Wednesday, 20 Mar 2019

You are here

IL-1 Suppression May Improve Dilated Cardiomyopathy


Interleukin-1 (IL-1) suppression helped reverse symptoms of dilated cardiomyopathy (DCM) for one patient in a case study that may implicate inflammation in the development of the condition.

The 57-year-old man with a 2-year history of DCM had been hospitalized for chronic fatigue and dyspnea secondary to heart failure (New York Heart Association class III). Transthoracic echocardiography (TTE) showed a severely dilated left ventricle; left ventricular ejection fraction (LVEF) was 28%. Cardiac catheterization showed normal coronary arteries.

After 6 months of optimal medical therapy, the patient remained symptomatic - - TTE again showing a severely dilated left ventricle.

With no autoantibodies in blood or viral genome sequences in endomyocardial biopsy, he was determined to meet criteria for idiopathic inflammatory DCM, Giulio Cavalli, MD, of San Raffaele Scientific Institute in Milan, Italy, and colleagues reported online in the Annals of Internal Medicine.

The patient was then started on subcutaneous injections of anakinra (Kineret, the recombinant form of the endogenous antagonist for the interleukin-1 receptor) - - and "the clinical response was striking," Cavalli's group said.

Within 2 weeks, the patient improved to New York Heart Association class I and had LVEF climb to 38%.

Four weeks in, LVEF rose even further, to 42%. There was no change in myocardial scarring, but myocardial edema nearly resolved and ventricular ectopic beats almost disappeared. A decrease in the serum interleukin-6 level (a measure of the amount of inflammation sustained by interleukin-1) confirmed that anakinra had effectively suppressed the inflammation, the researchers reported.

"This patient with DCM experienced what we believe to be unprecedented clinical improvement with use of anakinra to inhibit interleukin-1. Improvement began soon after anakinra administration and was obvious by every measure. The patient felt better and was able to lead a more normal life," they said.

Much is already known about the safety of anakinra from patients with rheumatologic conditions, according to Cavalli and colleagues, who said they believed "that this treatment and the role of chronic low-grade inflammation in DCM deserve further investigation."The inflammatory hypothesis in cardiovascular disease was validated last year in the CANTOS trial, in which another anti-inflammatory monoclonal antibody, canakinumab (Ilaris), reduced cardiovascular events by 15%.

That drug carries a cost of $16,000 per injection, which was once every 3 months in CANTOS. Anakinra, at the standard 100 mg per day dose, retails for about $1,000 per week.

Cavalli reported personal fees from SOBI and Novartis.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No Rise in Cancer Risk with Actemra

In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.

First Line IL-1 Inhibition in Systemic JIA

First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective as monotherapy, minimizing the need for glucocorticoids, a single-center prospective study found.

Impressive Survival of Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis

The drug retention rate of interleukin-1 inhibitors (IL-1) used to treat systemic juvenile idiopathic arthritis (JIA) appears to be quite high according to a new study. 

Safety Warnings for Higher Dose Tofacitinib

Pfizer has issued a press release regarding the safety of tofacitinib, citing higher rates of pulmonary embolism and death associated with the use of higher dose tofacitinib 10mg bid in rheumatoid arthritis (RA) patients treated in a long-term safety trial.  

Stopping Biologics Before Joint Surgery: Is Earlier Better?

Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a retrospective claims-based analysis found.